Highly multiplexed CRISPR‐Cas9‐nuclease and Cas9‐nickase vectors for inactivation of hepatitis B virus

CRISPR‐Cas9‐mediated genome‐editing technology contributes not only to basic genomic studies but also to clinical studies such as genetic correction and virus inactivation. Hepatitis B virus (HBV) is a major target for potential application of CRISPR‐Cas9 in eliminating viral DNA from human cells. However, the high stability of covalently closed circular DNA (cccDNA) makes it difficult to completely clear HBV infection. Here, we report highly multiplexed CRISPR‐Cas9‐nuclease and Cas9‐nickase vector systems that simultaneously target three critical domains of the HBV genome. Co‐transfection of an HBV‐expressing plasmid and all‐in‐one CRISPR‐Cas9 vectors resulted in significant reduction in viral replicative intermediates and extracellular hepatitis B surface and envelope antigens. In addition, successful fragmentation of the HBV genome was confirmed by DNA sequencing. Despite its high efficacy in suppressing HBV, no apparent off‐target mutations were detected by genomic cleavage detection assay and the small number of observed mutations was extremely rare and could only be detected by deep sequencing analysis. Thus, our all‐in‐one CRISPR‐Cas9‐nuclease and Cas9‐nickase vectors present a model for simultaneous targeting of multiple HBV domains, potentially contributing to a well‐designed therapeutic approach for curing HBV patients.

[1]  Eunji Kim,et al.  Targeted chromosomal deletions in human cells using zinc finger nucleases. , 2010, Genome research.

[2]  M. Imamura,et al.  Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus , 2005, Hepatology.

[3]  Chunsheng Dong,et al.  Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication. , 2015, Antiviral research.

[4]  Mengji Lu,et al.  CRISPR/Cas9-based tools for targeted genome editing and replication control of HBV , 2015, Virologica Sinica.

[5]  J. Joung,et al.  High-fidelity CRISPR-Cas9 variants with undetectable genome-wide off-targets , 2015, Nature.

[6]  G. Church,et al.  CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering , 2013, Nature Biotechnology.

[7]  K. Chayama,et al.  Multiplex genome engineering in human cells using all-in-one CRISPR/Cas9 vector system , 2014, Scientific Reports.

[8]  H. Varmus,et al.  The molecular biology of the hepatitis B viruses. , 1987, Annual review of biochemistry.

[9]  Yinqing Li,et al.  Crystal Structure of Staphylococcus aureus Cas9 , 2015, Cell.

[10]  D. Standring.  The Molecular Biology of the Hepatitis B Virus Core Protein , 2018 .

[11]  A. McCaffrey,et al.  Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  Martin J. Aryee,et al.  Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing , 2014, Nature Biotechnology.

[13]  D. Segal,et al.  How specific is CRISPR/Cas9 really? , 2015, Current opinion in chemical biology.

[14]  T. Shibata,et al.  Targeted mutagenesis in the sea urchin embryo using zinc-finger nucleases , 2010 .

[15]  B. Cullen,et al.  Targeting hepatitis B virus cccDNA using CRISPR/Cas9. , 2015, Antiviral research.

[16]  David A. Scott,et al.  Rationally engineered Cas9 nucleases with improved specificity , 2015, Science.

[17]  Xiangmei Chen,et al.  Dual gRNAs guided CRISPR/Cas9 system inhibits hepatitis B virus replication. , 2015, World journal of gastroenterology.

[18]  K. Woltjen,et al.  Nuclease‐mediated genome editing: At the front‐line of functional genomics technology , 2014, Development, growth & differentiation.

[19]  Ding-Shinn Chen,et al.  The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo , 2014, Molecular therapy. Nucleic acids.

[20]  T. Cathomen,et al.  Inactivation of Hepatitis B Virus Replication in Cultured Cells and In Vivo with Engineered Transcription Activator-Like Effector Nucleases , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[21]  David R. Liu,et al.  Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification , 2014, Nature Biotechnology.

[22]  平賀 伸彦.  Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C virus and its susceptibility to interferon , 2008 .

[23]  J. Hauber,et al.  CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X , 2015, Scientific Reports.

[24]  G. Lin,et al.  Application of CRISPR/Cas9 Technology to HBV , 2015, International journal of molecular sciences.

[25]  David A. Scott,et al.  Double Nicking by RNA-Guided CRISPR Cas9 for Enhanced Genome Editing Specificity , 2013, Cell.

[26]  Tetsushi Sakuma,et al.  Efficient TALEN construction and evaluation methods for human cell and animal applications , 2013, Genes to cells : devoted to molecular & cellular mechanisms.

[27]  Gérard Krause,et al.  Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013 , 2015, The Lancet.

[28]  J. Keith Joung,et al.  731. High-Fidelity CRISPR-Cas9 Nucleases with No Detectable Genome-Wide Off-Target Effects , 2016 .

[29]  David A. Scott,et al.  In vivo genome editing using Staphylococcus aureus Cas9 , 2015, Nature.

[30]  Peng Qiu,et al.  COSMID: A Web-based Tool for Identifying and Validating CRISPR/Cas Off-target Sites , 2014, Molecular therapy. Nucleic acids.

[31]  J. Keith Joung,et al.  Improving CRISPR-Cas nuclease specificity using truncated guide RNAs , 2014, Nature Biotechnology.

[32]  M. Ohmuraya,et al.  Production of knockout mice by DNA microinjection of various CRISPR/Cas9 vectors into freeze-thawed fertilized oocytes , 2015, BMC Biotechnology.